Clinical Trials
19 trialsNCT02135133 2026-03-17
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03133221 2025-06-27
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
University of Maryland, Baltimore
Phase 2 Completed
NCT02332980 2024-01-03
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Mayo Clinic
Phase 2 Completed
NCT02962401 2023-08-29
RemodelWM3
French Innovative Leukemia Organisation
Phase 2 Completed
NCT02968563 2022-01-21
Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Gilead Sciences
Phase 2 Completed
NCT02639910 2021-12-20
COSMOS
MorphoSys AG
Phase 2 Completed
NCT03576443 2021-10-13
ILIAD
Nordic Lymphoma Group
Phase 2 Completed
NCT02242045 2021-03-19
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
Gilead Sciences
Phase 1 Completed
NCT01088048 2021-03-18
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 1 Completed
NCT02779283 2020-05-26
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
Phase 1 Completed
NCT01569295 2020-03-10
Tugela
Gilead Sciences
Phase 3 Completed
NCT02603445 2020-02-24
Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL
Novartis
Phase 1 Completed
NCT01282424 2019-07-11
DELTA
Gilead Sciences
Phase 2 Completed
NCT01539512 2019-05-14
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Gilead Sciences
Phase 3 Completed
NCT01306643 2018-11-19
Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma
Gilead Sciences
Phase 1/2 Completed
NCT01393106 2018-11-19
Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
Gilead Sciences
Phase 2 Completed
NCT01644799 2018-01-30
Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT01838434 2018-01-30
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT00710528 2012-08-31
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies
Gilead Sciences
Phase 1 Completed